2024年,多家创新药企核心产品销售显著增长。康方生物新药销售收入超20亿元,同比增长25%,核心双抗卡度尼利、依沃西被纳入国家医保目录。迈威生物药品销售收入为1.45亿元,同比增长243.53%,地舒单抗营收同比增长230.17%至1.39亿元。亚盛医药实现收入9.81亿元,同比增长342%,主要受益于武田制药的选择权付款及耐立克®的强劲销售。耐立克®在中国的销售收入达到2.41亿元,同比增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.